Literature DB >> 21828953

The impact of cardiac resynchronization therapy in an end-stage heart failure patient with a left ventricular assist device as a bridge to recovery. A case report.

Jun Muratsu1, Masahiko Hara, Isamu Mizote, Yoshihiro Asano, Yasushi Sakata, Shunsuke Saito, Goro Matsumiya, Yoshiki Sawa, Issei Komuro.   

Abstract

A 15-year-old male with acute decompensated heart failure was referred to our hospital for left ventricular assist device (LVAD) implantation as a bridge to recovery. Despite optimal medication, repetitive LVAD off-pump test findings suggested that his cardiac function had not improved enough to perform LVAD removal. However, his cardiac function significantly improved with cardiac resynchronization therapy (CRT). He underwent LVAD explantation and was successfully discharged from the hospital. We describe the case of an end-stage heart failure patient who underwent successful LVAD removal with CRT. The effect of CRT was definitively evaluated with right heart catheterization during LVAD off-pump test.

Entities:  

Mesh:

Year:  2011        PMID: 21828953     DOI: 10.1536/ihj.52.246

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  3 in total

1.  Electrical devices for left ventricular dysfunction and heart failure: do we need revised guidelines?

Authors:  Maya Guglin; S Serge Barold
Journal:  J Interv Card Electrophysiol       Date:  2011-12-17       Impact factor: 1.900

2.  Impact of Cardiac Resynchronization Therapy on Left Ventricular Unloading in Patients with Implanted Left Ventricular Assist Devices.

Authors:  David M Tehrani; Sirtaz Adatya; Jonathan Grinstein; Daniel Rodgers; Nitasha Sarswat; Gene H Kim; Jayant Raikhelkar; Gabriel Sayer; Nir Uriel
Journal:  ASAIO J       Date:  2019-02       Impact factor: 2.872

3.  Computational Prediction of the Combined Effect of CRT and LVAD on Cardiac Electromechanical Delay in LBBB and RBBB.

Authors:  Aulia K Heikhmakhtiar; Ki M Lim
Journal:  Comput Math Methods Med       Date:  2018-11-14       Impact factor: 2.238

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.